STRS Ohio’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

STRS Ohio’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-3,700	Closed	-$12K	–	2290
2020 Q1	$12K	Hold	3,700	–	–	﹤0.01%	1932
2019 Q4	$22K	Hold	3,700	–	–	﹤0.01%	1969
2019 Q3	$15K	Hold	3,700	–	–	﹤0.01%	2001
2019 Q2	$48K	Buy	+3,700	New	+$45.3K	﹤0.01%	1934

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio's PHAS Position: Q2 2020 in Review

STRS Ohio sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2020, closing a stake of 3,700 shares — an estimated $12K sold.

STRS Ohio first reported a position in PHAS in Q2 2019 and held it in 4 quarters. The position peaked at $48K in Q2 2019. 60 funds tracked by Wall St. Rank hold PHAS as of Q2 2020.

STRS Ohio reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
STRS Ohio sold 3,700 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $12K.
STRS Ohio first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
STRS Ohio's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $48K in Q2 2019.
60 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on STRS Ohio's 13F filing for Q2 2020, filed 23 Jul 2020.